ArticleFrontiers in cardiovascular medicine2026
Evaluation of cardiovascular risk using smartwatch-measured pulse wave velocity in China: a nationwide cross-sectional study.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiovascular and cerebrovascular diseases, driven by arteriosclerosis, are China's leading causes of death. Smartwatch-measured pulse wave velocity (SW-PWV) is an algorithm-derived estimate of carotid-femoral pulse wave velocity (cfPWV) generated using a built-in machine-learning algorithm. A previous validation study showed good agreement between smartwatch-estimated cfPWV and Complior Analyse measurements, with a concordance correlation coefficient of 0.9045 and a mean absolute error of 0.66 m/s. Objective: This study aimed to describe the distribution of smartwatch-measured pulse wave velocity (SW-PWV) according to age, sex, and body mass index (BMI), and to investigate its cross-sectional associations with cardiovascular risk factors and established cardiovascular disease (CVD). Methods: This cross-sectional study analyzed 165,549 users who completed at least one valid SW-PWV measurement using compatible Huawei smartwatches between December 2020 and August 2022. Analyses of cardiovascular risk factors and CVD were restricted to 35,402 users who completed the "Vascular Health" app questionnaire, in which physician-diagnosed conditions were self-reported according to predefined criteria. A threshold of 10 m/s, adapted from guideline recommendations for cfPWV, was explored for SW-PWV. Spearman's correlation, Kruskal-Wallis test, multiple regression, and Mann-Whitney Results: SW-PWV correlated positively with age, male sex, and BMI. After age- and BMI-stratification, SW-PWV increased progressively across all cohorts. Average SW-PWV was significantly higher in males than in females. SW-PWV was significantly elevated in participants with hypertension, diabetes, dyslipidemia, coronary heart disease, stroke, and carotid plaque, with hypertension and carotid plaque exhibiting the strongest correlations. SW-PWV demonstrated moderate discrimination for prevalent CVD (area under the curve = 0.71). When applying the guideline-recommended cfPWV threshold of 10 m/s to SW-PWV, sensitivity was 13.6% and specificity was 96.7%. Conclusion: In this cross-sectional study, SW-PWV was associated with age, sex, and BMI, with SW-PWV ≥10 m/s linked to a higher prevalence of cardiovascular risk factors and CVD. These findings suggest that the guideline-derived 10 m/s threshold of cfPWV might serve as a preliminary or exploratory threshold reference for SW-PWV, though direct validation against conventional cfPWV and prospective longitudinal studies are required before clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.